Intest Res.  2022 Apr;20(2):269-273. 10.5217/ir.2021.00064.

Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis

• Kamat N
• Vuyyuru SK
• Kedia S
• Sahu P
• Kante B
• Kumar P
• Ranjan MK
• Singh MK
• Kumar S
• Sachdev V
• Makharia G
• Ahuja V

• KMID: 2529573
• DOI: http://doi.org/10.5217/ir.2021.00064

Figure

• 

  Fig. 1. Receiver operating characteristic (ROC) curve of IBD-VAS, IBD control-8 in predicting clinical remission. IBD, inflammatory bowel disease; VAS, visual analog scale.

Reference

1. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006; 4:1491–1501.

2. Burke LB, Kennedy DL, Miskala PH, Papadopoulos EJ, Trentacosti AM. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther. 2008; 84:281–283.

3. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014; 12:1246–1256.

4. Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut. 2014; 63:1092–1102.

5. Kim DJ, Jeoun YM, Lee DW, Koo JS, Lee SW. Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis. Intest Res. 2018; 16:563–570.

6. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005; 54:782–788.

7. Dudeja P, Bahuguna P, Singh A, Bhatnagar N. Refining a socioeconomic status scale for use in community-based health research in India. J Postgrad Med. 2015; 61:77–83.

8. Keller R, Mazurak N, Fantasia L, et al. Quality of life in inflammatory bowel diseases: it is not all about the bowel. Intest Res. 2021; 19:45–52.

9. Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol. 2012; 12:108.

10. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD). Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160:1570–1583.

11. Dulai PS, Battat R, Barsky M, et al. Incorporating fecal calprotectin into clinical practice for patients with moderate-to-severely active ulcerative colitis treated with biologics or smallmolecule inhibitors. Am J Gastroenterol. 2020; 115:885–894.

12. Bertani L, Blandizzi C, Mumolo MG, et al. Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study. Clin Transl Gastroenterol. 2020; 11:e00174.

13. Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2016; 150:96–102.

14. Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013; 19:1034–1042.

15. Walsh A, Kormilitzin A, Hinds C, et al. Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis: a prospective analysis. J Crohns Colitis. 2019; 13:424–430.

16. Samaan M, Cunningham G, Tamilarasan G, et al. P143 Validation of the two-item UC PRO2 against SCCAI, biochemical disease activity and quality of life. Gut. 2021; 70(Suppl 1):A116–A117.